AGWCA
CORT icon

Annis Gardner Whiting Capital Advisors’s Corcept Therapeutics CORT Stock Holding History

Annis Gardner Whiting Capital Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2
Closed -$81 – 522
2026
Q1 		$81 Sell
2
-156
-99% -$5.83K ﹤0.01% 1295
2025
Q4 		$5.5K Sell
158
-27
-15% -$2.12K ﹤0.01% 856
2025
Q3 		$15.4K Buy
185
+163
+741% +$11.8K ﹤0.01% 647
2025
Q2 		$1.61K Buy
+22
New +$1.59K ﹤0.01% 999

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Annis Gardner Whiting Capital Advisors's CORT Position: Q2 2026 in Review

Annis Gardner Whiting Capital Advisors sold out of Corcept Therapeutics (CORT) in Q2 2026, closing a stake of 2 shares — an estimated $81 sold.

Annis Gardner Whiting Capital Advisors first reported a position in CORT in Q2 2025 and held it in 4 quarters. The position peaked at $15.4K in Q3 2025. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Annis Gardner Whiting Capital Advisors reported no remaining Corcept Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Annis Gardner Whiting Capital Advisors sold 2 Corcept Therapeutics shares in Q2 2026, an estimated $81.
  • Annis Gardner Whiting Capital Advisors first reported a position in Corcept Therapeutics in Q2 2025 and held it in 4 quarters.
  • Annis Gardner Whiting Capital Advisors's Corcept Therapeutics position peaked at $15.4K in Q3 2025.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Annis Gardner Whiting Capital Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.